Mepolizumab helps patients with refractory Churg-Strauss syndrome

Mepolizumab, an anti-IL5 monoclonal antibody, increased remission rates, cut exacerbations in half and reduced the need for ongoing corticosteroid therapy in patients with refractory cases of the rare autoimmune disease Churg-Strauss Syndrome, according to research.